RA Capital Management LLC Buys New Holdings in AVEO Pharmaceuticals, Inc. (AVEO)
RA Capital Management LLC bought a new position in shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 8,435,584 shares of the biopharmaceutical company’s stock, valued at approximately $18,727,000. AVEO Pharmaceuticals makes up about 2.1% of RA Capital Management LLC’s holdings, making the stock its 15th biggest holding. RA Capital Management LLC owned about 7.64% of AVEO Pharmaceuticals as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in AVEO. Sabby Management LLC purchased a new stake in shares of AVEO Pharmaceuticals during the first quarter worth $513,000. Perceptive Advisors LLC grew its holdings in shares of AVEO Pharmaceuticals by 64.3% during the first quarter. Perceptive Advisors LLC now owns 5,108,808 shares of the biopharmaceutical company’s stock worth $3,014,000 after buying an additional 2,000,000 shares in the last quarter. Paloma Partners Management Co purchased a new stake in shares of AVEO Pharmaceuticals during the first quarter worth $184,000. UBS Oconnor LLC purchased a new stake in shares of AVEO Pharmaceuticals during the first quarter worth $291,000. Finally, Clear Harbor Asset Management LLC purchased a new stake in shares of AVEO Pharmaceuticals during the second quarter worth $289,000. 53.76% of the stock is owned by institutional investors and hedge funds.
A number of equities research analysts have recently issued reports on AVEO shares. Piper Jaffray Companies reaffirmed a “buy” rating and set a $3.50 target price on shares of AVEO Pharmaceuticals in a report on Thursday, August 10th. ValuEngine raised shares of AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, June 24th. Zacks Investment Research raised shares of AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a report on Monday, July 24th. FBR & Co reaffirmed an “outperform” rating and set a $3.00 target price on shares of AVEO Pharmaceuticals in a report on Thursday, July 13th. Finally, BidaskClub raised shares of AVEO Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 16th. One research analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. AVEO Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $3.42.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://theolympiareport.com/2017/10/06/ra-capital-management-llc-buys-new-holdings-in-aveo-pharmaceuticals-inc-aveo.html.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) traded down 4.30% during midday trading on Friday, hitting $3.78. 5,111,292 shares of the stock were exchanged. The stock’s market cap is $447.20 million. The firm has a 50-day moving average price of $3.58 and a 200-day moving average price of $1.91. AVEO Pharmaceuticals, Inc. has a one year low of $0.50 and a one year high of $4.24.
AVEO Pharmaceuticals Company Profile
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Want to see what other hedge funds are holding AVEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO).
Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.